J&J launches Largest COVID-19, Single-Shot Vaccine Phase 3 Clinical Trials, an Industrial Info Market Brief
Attachment: Map
On Wednesday, September 21, drug giant Johnson & Johnson began Phase 3 clinical trials that will expand to an expected 60,000 volunteers in the U.S., South Africa and a half dozen South American countries. This is the largest trial to date of all COVID-19 vaccines in development.
Key features of the promising drug include the fact it does not need to be frozen and will likely only require one shot rather than two. Paul Stoffels, chief scientific officer at Johnson & Johnson, said the company may be able to determine the vaccine's safety and efficacy by the end of the year.
